Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 30, 2024

Durable Benefit From PARP Inhibitors in Patients With Metastatic Prostate Cancer in Routine Practice According to Molecular Subgroups

ESMO Open

 

Additional Info

ESMO Open
Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing
ESMO Open 2024 Sep 09;9(9)103684, D Triner, RP Graf, RW Madison, O Gjoerup, H Tukachinsky, JS Ross, JCF Quintanilha, G Li, HH Cheng, CC Pritchard, AJ Zurita, Q Qin, T Zhang, N Agarwal, ZR Reichert, J Mateo, M Cieslik, TM Morgan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.


Further Reading